New COVID Vaccines Approved Amid Rising Cases

The U.S. has approved updated COVID-19 vaccines from Moderna, Pfizer, and Novavax, coinciding with an increase in cases nationwide. Data from the CDC indicates a test positivity rate near 5% as of August 15, 2026, the highest since February.

The new vaccines, including Moderna's Spikevax and mNexspike, Pfizer's Comirnaty, and Novavax/Sanofi's protein-based Nuvaxovid, all target the JN.1-lineage XFG variant. This approach mirrors the annual reformulation of flu vaccines based on circulating strains.

Eligibility for the updated shots primarily focuses on individuals aged 65 and older and those with underlying health conditions that elevate their risk of severe COVID-19. These comorbidities can include conditions such as pregnancy, chronic lung disease, depression, and obesity. Doctors affirm that anyone desiring a vaccine should be able to obtain one, even if administered "off-label."

These updated vaccines are expected to be shipped immediately, with high-risk individuals advised to get vaccinated promptly due to increasing national COVID activity. While many doctor's offices will stock the vaccines, some states may require CDC sign-off for pharmacy distribution. Doctors emphasize the value of mRNA vaccines for their rapid development capabilities and stress that all approved COVID vaccines are effective in preventing severe disease, hospitalization, and death.